Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo Growth
Syndax Pharmaceuticals (SNDX) reported a narrower Q3 loss of $49.43M, down from $60.71M YoY, as revenue jumped 82% to $83.30M. Revuforj sales rose 90% to $60.74M, while Niktimvo contributed $22.55M. R&D expenses increased, but SG&A expenses declined. The company maintained its FY26 outlook and provided clinical trial updates.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial metrics and guidance, offering traders a basis for short‑term positioning.
Market read
Earnings beat on revenue with narrowed loss may prompt modest buying interest, but ongoing loss and cash burn keep risk elevated.
What to watch
Upcoming clinical data releases and cash runway may dominate future price action.
Background
Syndax Pharmaceuticals reported its Q3 2026 results, highlighting revenue growth from its menin inhibitor Revuforj and antibody Niktimvo, while narrowing its net loss.
Ticker impact
Q3 loss narrowed to $49.43M and revenue jumped 82% to $83.30M, with Revuforj sales up 90%.
likely modest upside as market prices in revenue beat and narrowed loss
Revenue beat and loss narrowing are positive, but ongoing loss and high cash burn keep risk elevated.
Market effects
stronger revenue growth may lift other commercial-stage biotech stocks
US biotech sector could see slight positive bias
limited to biotech investors, no broad market effect
Counterpoint
Despite revenue beat, continued loss and high cash burn could pressure the stock lower.
Key entities
- companySyndax Pharmaceuticals, Inc.
Commercial-stage biopharma focused on cancer therapies.
